reason report
bottom line deliv strong quarter continu
growth momentum across segment importantli
momentum seem sustain admittedli
zytiga hold better gener expect
fulli sustain view even ex zytiga estim pharma
still grew ytd key core drug like darzalex imbruvica
tremfya stelara deliv strong double-digit growth
medic devic growth acceler larg driven innov
new product launch offset competit headwind price
growth momentum continu pharma drive above-
market growth medic devic build momentum consum
improv growth outlook margin profil look
beyond see clear line sight acceler sale growth
driven number potenti driver improv outlook go
forward includ continu strong double-digit growth key core
new drug zytiga comp get easier
medic devic growth reacceler driven new product
complex cervic spine drug-elut contact lend vision
orthotaxi fda submiss earli launch
consum turnaround continu relaunch babi brand
growth dr ci labo becom organ lap
acquisit share trade reaction strong
result inclin think litig overhang limit
share out-performance yesterday vs would otherwis
acknowledg on-going litig could remain
overhang continu limit near-term upsid gotten
posit news litig front sinc earn report
attempt settl outstand opioid litig
oklahoma judg cut prior rule damag
ultim believ litig issu manag
resolv pend case next month
share appreci reflect strong fundament
improv outlook across busi
reiter op pt view remain rel safe
volatil market investor compani digest
potenti impact polit uncertainti abroad
solid dividend yield believ continu
deliv averag return sharehold pt
appli price-to-earnings ep assum multipl
expans line large-cap med-tech vs
current price-to-earnings ep
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
compani inform svb leerink llc research
revenu mm ep includ stock compens expens
sale estim move higher reflect higher organ growth
sale estim move y/i oper
report vs
prior ep estim move lower
despit higher sale estim reflect lower incom per
manag commentari earn call
rate share outperform price target johnson johnson
histor repres defens stock view johnson johnson also
repres growth acceler stori beyond compani continu
execution-driven turnaround medic devic consum busi offset
pharma patent expir robust growth core drug new launch continu
believ johnson johnson drive sustain organ mid-single-digit top-lin growth
even better high-single-digit bottom-lin growth long-term help strong growth
core new drug stelara tremfya imbruvica darzalex continu
innovation/in-licens re-launch babi brand consum continu
improv medic devic busi ultim return sustain
solid mid-single-digit top-lin growth trajectori potenti above-market growth
dividend yield strong free cash flow gener believ share
repres attract total return vehicl investor
next month believ share trade price target price
target appli price-to-earnings multipl ep estim share current trade
ep estim large-cap med-tech group rang
price target assum see multipl
expans line broader comp group compani manag top-
line headwind continu drive oper leverag -- posit
sustain ep out-performance view total return capabl attract
increasingli volatil stock market environ like attract fund riskier area
risk includ failur success integr auri potenti futur acquisit failur
resolv outstand consum consent decre success re-launch product
product recal failur advanc late-stag pipelin success launch
new product protract recoveri procedur volum trend lack real
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu breakdown come first order analyt visibl alpha
consensu
compani report first order analyt consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
revenu
consensu incom statement item includ contributor factset
consensu detail revenu breakdown come first order analyt visibl alpha
consensu
compani report first order analyt consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
compani report svb leerink estim
johnson johnson sale y/i
world-wide sale billion usd
oper ex fx acquisit
oper ex fx acquisit
oper ex fx acquisit
world-wide sale billion usd
oper ex fx acquisit
oper ex fx acquisit
oper ex fx acquisit
world-wide sale billion usd
oper ex fx acquisit
oper ex fx acquisit
oper ex fx acquisit
world-wide sale billion usd
oper ex fx acquisit
oper ex fx acquisit
oper ex fx acquisit
y/i growth report fx
impact expect oper growth
rang expect adjust
oper growth ex acq /div
rang
declin report fx
impact expect oper growth
rang expect adjust
oper growth ex acq /div
rang
declin report fx
impact expect oper growth
rang expect adjust
oper growth ex acq /div
rang
declin report fx
growth rang
acq /div rang
report ex fx
report ex fx
report ex fx
report ex fx
report
report
ex olysio ex acquisit
expect expand
margin bp
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
neg fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
adjust ep report
reflect growth ep
oper growth
posit fx impact
expect fx nat impact gross
margin y/i
expect fx impact gross margin
expect fx impact gross margin
expect fx impact gross margin
expect fx impact gross margin
expect complet
remain share
repurchas
expect complet
share repurchas
expect complet
share repurchas
expect complet
share repurchas
comment mileston
nanosuspens inject
continu file number line extens xarelto
 vte prophylaxi ambulatori cancer patient receiv chemo high-risk vte phase
 infrainguin revascular phase
 pediatr vte phase
 treatment ckd patient phase eu
 resist hypertens phase eu
 psorat arthriti phase eu
 crohn diseas phase eu
 pediatr psoriasi phase eu
 juvenil idiopath arthriti jia phase
 juvenil idiopath arthriti jia phase
 pediatr psoriasi phase eu
 pediatr psoriasi year old phase eu
 lupu phase eu
 hiv infect phase eu
 monoval ebola viru vaccin phase eu
 influenza phase eu
 treatment-resist depress approv file eu
 major depress disord immin risk suicid phase eu
 relaps multipl sclerosi phase eu
 treatment schizophrenia phase eu
 relaps refractori mm prior line w/pomdex phase eu
 relaps refractori multipl myeloma w/carfilzomib/dex sponsor phase eu
 amyloidosi ami phase eu
 subcutan formul patient relaps refractori multipl myeloma columba
smolder multipl myeloma phase eu
 frontlin multipl myeloma transplant inelig combin w/ bortezomib lenalidomid dexamethason
cepheu phase eu
 frontlin multipl myeloma transplant elig combin w/ bortezomib lenalidomid dexamethason
perseu phase eu
imbruvica differenti efficaci toler durabl respons well-posit becom standard care b-
cell malign pursu sever new indic imbruvica enabl reach addit
patient per year file imbruvica includ
 treatment nave patient mantl cell lymphoma combin bendamustin rituximab random studi mcl-
 phase eu
 relapsed/refractori patient indol non-hodgkin lymphoma combin bendamustin rituximab r-
chop random studi phase eu
 previous untreat relapsed/refractori patient waldenstrom macroglobulinemia combin rituximab
 approv file eu
 frontlin chronic lymphocyt leukemia young combin rituximab ecog phase
 frontlin chronic lymphocyt leukemia combin obinutuzumab approv file eu
 frontlin chronic lymphocyt leukemia combin venetoclax fix durat glow phase eu
 frontlin chronic graft-versus-host-diseas cgvhd phase eu
 relapsed/refractori patient mantl cell lymphoma combin venetoclax phase
receiv compound aragon part acquisit address much larger pre-metastat prostat
cancer market oral androgen receptor inhibitor men non-metast castration-resist prostrat cancer
 metast hormon sensit prostat cancer phase eu
 local prostat cancer phase eu
 prostat cancer metast castrat resist chemotherapi nave phase eu
 urotheli cancer approv phase eu
 prostat cancer metastat castration-resist phase iib eu
 prostat cancer metastat castration-resist combin abirateron acet prednison phase
 fontan-palli adolesc year old adult patient phase eu
 pediatr pulmonari arteri hypertens phase eu
 pulmonari arteri hypertens phase eu
 chronic thromboembol pulmonari hypertension- phase eu
inform accur date hereof best compani knowledg johnson johnson assum oblig updat inform
invokana licens mitsubishi tanab pharma corpor symtuza develop collabor edur str develop collabor viiv healthcar xarelto co-
develop bayer healthcar paliperidon palmit includ technolog licens inc darzalex licens genmab a/ imbruvica develop collabor pharmacycl llc
compani pimodivir licens inc
compani report svb leerink estim
